CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 4,866	$ 10,813	$ 17,964	$ 38,606
Operating expenses:
Cost of goods sold	1,558	3,055	5,566	5,136
Research and development	25,451	24,691	80,095	65,869
General and administrative	6,755	6,912	21,191	23,829
Total operating expenses	33,764	34,658	106,852	94,834
Operating loss	(28,898)	(23,845)	(88,888)	(56,228)
Other income, net	866	665	2,712	1,093
Net loss	$ (28,032)	$ (23,180)	$ (86,176)	$ (55,135)
Net loss per share:
Basic	$ (0.52)	$ (0.43)	$ (1.59)	$ (1.03)
Diluted	$ (0.52)	$ (0.43)	$ (1.59)	$ (1.03)
Weighted average shares:
Basic	54,235,695	53,726,123	54,038,239	53,616,753
Diluted	54,235,695	53,726,123	54,038,239	53,616,753
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 291	$ (101)	$ 1,233	$ (1,790)
Total comprehensive loss	(27,741)	(23,281)	(84,943)	(56,925)
Collaborative revenue
Revenue:
Total revenue	2,471	7,443	10,631	15,446
Commercial supply revenue
Revenue:
Total revenue	1,252	$ 3,370	5,843	8,160
Royalty revenue
Revenue:
Total revenue	167		415
License and milestone fees
Revenue:
Total revenue	910		910	$ 15,000
Clinical compound revenue
Revenue:
Total revenue	$ 66		$ 165